Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention

• Published in: Cardiovascular diabetology Vol. 21; no. 1; pp. 270 - 17
• Main Authors: Zhou, Xiao-Dong, Cai, Jingjing, Targher, Giovanni, Byrne, Christopher D., Shapiro, Michael D., Sung, Ki-Chul, Somers, Virend K., Chahal, C. Anwar A., George, Jacob, Chen, Li-Li, Zhou, Yong, Zheng, Ming-Hua
• Format: Journal Article
• Language: English
• Published: England BioMed Central 03.12.2022; BMC
• Subjects: Cardiology; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cohort analysis; Fatty liver; Heart attacks; Heart Disease Risk Factors; Hepatitis; Humans; Liver diseases; Metabolic dysfunction-associated fatty liver disease (MAFLD); Metabolism; Morbidity; Mortality; Non-alcoholic fatty liver disease (NAFLD); Non-alcoholic Fatty Liver Disease - diagnosis; Non-alcoholic Fatty Liver Disease - epidemiology; Pharmacotherapies; Review; Risk Factors; Stroke; Terminology; Pharmacotherapies; Metabolic dysfunction-associated fatty liver disease (MAFLD); Cardiovascular disease; Risk factors; Non-alcoholic fatty liver disease (NAFLD)

The newly proposed term “metabolic dysfunction-associated fatty liver disease” (MAFLD) is replacing the old term “non-alcoholic fatty liver disease” (NAFLD) in many global regions, because it better reflects the pathophysiology and cardiometabolic implications of this common liver disease. The propo...